{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:28:31Z","timestamp":1792290511022,"version":"4.4.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T00:00:00Z","timestamp":1194998400000},"content-version":"vor","delay-in-days":3757,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Apheresis"],"published-print":{"date-parts":[[1997,8]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Hypercholesterolemia can be adequately controlled by appropriate diet and maximum lipid lowering drug therapy in most patients. Nevertheless, there exists a group of patients, including those with familial hypercholesterolemia (FH), who remain at high risk for the development or progression of premature coronary heart disease (CHD). For these patients additional measures such as surgery and low\u2010density lipoprotein (LDL) apheresis have to be considered. The objective of this multicenter trial, which included 30 clinical centers (28 in Germany and one each in Scotland and Luxembourg), was to determine if repeated LDL apheresis using the Liposorber LAIS system (Kaneka Corporation, Osaka, Japan) could lead to an additional acute and time averaged lowering of total cholesterol (TC) and LDL\u2010cholesterol (LDL\u2010C) in severely hypercholesterolemic patients whose cholesterol levels could not be controlled by appropriate diet and maximum drug therapy. A total of 6,798 treatments were performed on 120 patients, including 8 with homozygous FH, 75 with heterozygous FH, and 37 with unclassified FH or other hyperlipidemias from 1988 through 1994. The mean TC and mean LDL\u2010C levels at baseline were 410.0 mg\/dl and 333.9 mg\/dl, respectively. LDL apheresis was performed once a week or at least once every 2 weeks in all patients. During treatment with the Liposorber system the mean acute percentage reduction was 52.6% for TC and 63.1% for LDL\u2010C. Very low density lipoprotein cholesterol (VLDL\u2010C) and triglycerides (TG) were also substantially reduced to 60.6% and 47.5%, respectively. Fibrinogen, a potential risk factor for CHD, was reduced by 26.2%. In contrast, the mean acute reduction of high density lipoprotein (HDL) was only 3.4%. During the course of the treatment, the time averaged levels of TC and LDL\u2010C were reduced by approximately 39% and 50%, respectively, compared to baseline levels. The adverse events (AEs) were those generally associated with extra\u2010corporeal treatments. The most common AE was hypotension, with 69 episodes corresponding to 1 % of all treatments reported in 44 of the 120 patients treated. All other kinds of AEs occurred in less than 0.2% of the treatments. The treatment with the Liposorber LA\u201015 system was overall well tolerated. It should be noted, however, that a more severe type of hypotensive reaction associated with flush, bradycardia, and dyspnea was reported in patients taking concomitant angiotensin converting enzyme (ACE) inhibitor medication. Except for such anaphylactoid\u2010like reactions associated with the intake of ACE inhibitors, the Liposorber LA\u201015 system represents a safe and effective therapeutic option for patients suffering from severe hypercholesterolemia that could not be adequately controlled by diet and maximum drug therapy.<\/jats:p>","DOI":"10.1111\/j.1744-9987.1997.tb00145.x","type":"journal-article","created":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T19:40:31Z","timestamp":1195069231000},"page":"242-248","source":"Crossref","is-referenced-by-count":20,"title":["Low\u2010Density Lipoprotein Apheresis for Prevention and Regression of Atherosclerosis: Clinical Results"],"prefix":"10.1111","volume":"1","author":[{"given":"R.","family":"Bambauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Olbricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schoeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200073024"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continued and graded?: Findings in 356,222 primary screenings of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler J.","year":"1986","journal-title":"JAMA"},{"key":"e_1_2_1_4_2","volume-title":"Procam\u2010Trial (The Muenster Cardiovascular Trial)","author":"Assmann AG","year":"1986"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease","volume":"251","author":"Lipid Research Clinics Program.","year":"1984","journal-title":"JAMA"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91338-6"},{"issue":"23","key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"et al. Beneficial effects of colestipolniacin on coronary atherosclerosis: A 4\u2010year follow\u2010up","volume":"264","author":"Cashin\u2010Hemphill L.","year":"1990","journal-title":"JAMA"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011083231901"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91656-U"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with a combined drug regimen","volume":"264","author":"Kane JP","year":"1990","journal-title":"JAMA"},{"key":"e_1_2_1_12_2","unstructured":"National Cholesterol Education Program.Report of the expert panel on detection evaluation and treatment of high blood cholesterol in adults. NIH Publication No. 88\u201329251988."},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel TT)","volume":"269","author":"National Cholesterol Education Program.","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_14_2","unstructured":"European Atherosclerosis Society.The recognition and management of hyperlipidaemia in adults\u2014A Policy statement of the European Atherosclerosis Society.Eur Heart J1988."},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1001\/jama.1986.03380200067023","article-title":"Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: A multicenter study","volume":"256","author":"The Lovastatin Study Group II.","year":"1986","journal-title":"JAMA"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90589-3"},{"issue":"24","key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1001\/jama.1987.03400240064025","article-title":"3\u2010Hydroxy\u20103\u2010Methylglutaryl\u2010Coenzyme A reductase inhibitors in the treatment of hypercholesterolemia","volume":"258","author":"Hoeg JM","year":"1987","journal-title":"JAMA"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-5-616"},{"key":"e_1_2_1_19_2","first-page":"1121","article-title":"Treatment of heterozygous familial hypercholesterolemia with lipid\u2010lowering drugs","volume":"9","author":"Illingworth DR","year":"1989","journal-title":"Arteriosclerosis"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-3-339"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)93005-6"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010043231404"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412273112603"},{"key":"e_1_2_1_24_2","first-page":"1377","article-title":"Formes homozygotes cutaneo\u2010tendineuses de xanthomastose hypercholesterolemique dans une observation familiale exemplaire. Essi de plasmapherese a litre de traitement heroique","volume":"118","author":"Genne De","year":"1967","journal-title":"Bull Mem Soc Med Hasp Paris"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92412-0"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920040204"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1991.tb01384.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91736-0"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.5.6.613"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(87)90089-X"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(87)90037-0"},{"key":"e_1_2_1_32_2","first-page":"87","article-title":"Effects on coronary atherosclerosis of long\u2010term treatment of familial hypercholesterolemia by LDL\u2010apheresis","volume":"23","author":"Mabuchi H.","year":"1988","journal-title":"Contrib Infusion Ther"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat1973.17.4_517","article-title":"Clinical findings of long\u2010term treatment with LDL\u2010apheresis (in Japanese)","volume":"17","author":"Shinomiya M.","year":"1989","journal-title":"J Jpn Atheroscler Soc"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1992.tb00290.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90352-Y"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93315-E"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92673-4"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92542-2"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199402000-00011"},{"key":"e_1_2_1_40_2","unstructured":"Aengevaeren JP.The LDL\u2010Apheresis Atherosclerosis Regression Study (LAARS) of University Hospital Nijmegen; Presented at the XVth Congress of the European Society of Cardiology Nice France1993."},{"key":"e_1_2_1_41_2","first-page":"83","volume-title":"The Treatment of Severe Hypercholesterolemia: Can We Impact Disease Course?","author":"Tait Y.","year":"1992"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(92)90170-L"},{"key":"e_1_2_1_43_2","first-page":"14","article-title":"Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low\u2010density lipoproteinapheresis: 1 year follow\u2010up study","volume":"16","author":"Kitabatake A.","year":"1994","journal-title":"Clinical Ther"},{"key":"e_1_2_1_44_2","unstructured":"NishimuraS. on behalf of the L\u2010CAPS group. Regression of coronary artery disease in familial hypercholesterolemia: Japan LDL\u2010Apheresis Coronary Atherosclerosis Prospective Study (L\u2010CAPS). L\u2010CAPS Group Yokohama Rosal Hospital (in press)."}],"container-title":["Therapeutic Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.1997.tb00145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.1997.tb00145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T12:51:03Z","timestamp":1698411063000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.1997.tb00145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["10.1111\/j.1744-9987.1997.tb00145.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.1997.tb00145.x","archive":["Portico"],"relation":{},"ISSN":["1091-6660","1526-0968"],"issn-type":[{"value":"1091-6660","type":"print"},{"value":"1526-0968","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8]]}}}